prolaio eVO2peak Module vs Zio AT ECG Monitoring System
AI Verdict
Choose prolaio eVO2peak Module if…
Choose the Prolaio eVO2peak Module if your primary goal is to estimate peak oxygen consumption (eVO2peak) for cardiovascular risk stratification and functional capacity assessment. This tool is ideal for clinical evaluation and research that leverages existing real-world patient data from third-party FDA-cleared wearable sensors to provide high-density, longitudinal insights into cardiovascular health.
View prolaio eVO2peak Module →Choose Zio AT ECG Monitoring System if…
Choose the Zio AT ECG Monitoring System if you need continuous, long-term (up to 14 days) ECG monitoring specifically for the detection and diagnosis of cardiac arrhythmias. This system is best suited for identifying both symptomatic and asymptomatic cardiac events with real-time data transmission capabilities, providing comprehensive reports for clinicians managing patients with suspected or known arrhythmias.
View Zio AT ECG Monitoring System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | prolaio eVO2peak Module | Zio AT ECG Monitoring System |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud | Cloud-based (data analytics and clinician portal) |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Zio AT ECG Monitoring SystemTool B, the Zio AT ECG Monitoring System, offers a more comprehensive and integrated user experience with a dedicated wearable patch, patient mobile app, and clinician portal. This end-to-end system likely provides a more streamlined workflow for both patients and providers compared to Tool A, which is a software module processing data from third-party sensors.
Clinical Value
Zio AT ECG Monitoring SystemBoth tools offer significant clinical value and are FDA-cleared. However, Tool B's continuous, long-term ECG monitoring for arrhythmia detection provides direct diagnostic and management information for a broad range of cardiac conditions. Tool A provides an estimation of eVO2peak as an adjunctive aid, which is a valuable prognostic marker but may have a more focused clinical application compared to direct arrhythmia detection.
Pricing & Value
TieBoth Tool A and Tool B require direct contact for pricing information, indicating a lack of public transparency regarding their cost structures. While Tool B mentions service fees for monitoring and analysis, specific figures are not disclosed for either product, making a direct comparison of value impossible.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and offering Business Associate Agreements (BAAs). Both are cloud-based, indicating scalability and accessibility. Without further details on specific integration capabilities with Electronic Health Records (EHRs) or other enterprise systems, it is difficult to distinguish a clear winner.
Innovation
Zio AT ECG Monitoring SystemBoth tools leverage FDA-cleared deep learning AI for their respective functions. Tool B's innovation lies in its integrated system for continuous, long-term (up to 14 days) and AI-driven arrhythmia detection via a wearable patch, coupled with real-time data transmission. This comprehensive approach for remote cardiac monitoring represents a significant and potentially disruptive innovation in the field, offering a more complete solution than Tool A's estimation of eVO2peak from various sensor inputs.
Support & Docs
Zio AT ECG Monitoring SystemBased on web searches, iRhythm Technologies (Tool B) appears to have a more established and publicly accessible support and documentation infrastructure, including resources for both clinicians and patients. Prolaio (Tool A), as a clinical intelligence company, likely offers enterprise-level support, but its public documentation and support resources are less readily apparent.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | prolaio eVO2peak Module | Zio AT ECG Monitoring System |
|---|---|---|
| Name | prolaio eVO2peak Module | Zio AT ECG Monitoring System |
| Company | Prolaio | iRhythm Technologies, Inc. |
| Primary Function | Estimates peak oxygen consumption (eVO2peak) using real-world patient data. | Continuous, AI-powered ECG monitoring for long-term arrhythmia detection. |
| Key Data Inputs/Hardware | Demographic data, single-lead ECG, triaxial accelerometry inputs; processes data from qualified third-party FDA-cleared wearable medical sensors. | Wearable Zio AT patch for continuous ECG recording; wireless gateway for real-time data transmission. |
| AI Algorithm Focus | Applies a locked deep-learning model for eVO2peak estimation. | FDA-cleared deep-learned AI algorithm (ZEUS System) for arrhythmia detection. |
| Specialties | Cardiology, Physical Medicine & Rehab, Sports Medicine | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring prolaio eVO2peak Module and Zio AT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring prolaio eVO2peak Module or Zio AT ECG Monitoring System
Backers
Who funded each tool's parent company.